GlassScriptPhysician profile
Sueyi Lai
NPI 1275765174
$4,706.18
in general payments reported to CMS, 2019-2025
32 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.73 · 2023: $713 · 2024: $2,200 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,285 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $88.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.23 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $88.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,625.42 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $373.08 | 2024-2025 | Opdivo, Krazati |
| Astrazeneca Pharmaceuticals LP | $283.08 | 2023-2025 | Lynparza, Enhertu, Imfinzi |
| Celgene Corporation | $259.51 | 2023-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $250.78 | 2024-2025 | |
| Daiichi Sankyo INC. | $219.29 | 2023-2025 | Enhertu, Injectafer |
| Gilead Sciences, INC. | $217.52 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $170.22 | 2023-2025 | Xtandi, Xospata, Padcev |
| Abbvie INC. | $136.54 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.08 | 2023-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $108.58 | 2024-2025 | Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $106.84 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $100.76 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Genzyme Corporation | $87.99 | 2023-2025 | |
| Seagen INC. | $72.63 | 2023 | Padcev, Tukysa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $60.10 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $54.75 | 2024 | Ojjaara |
| Eisai INC. | $54.49 | 2023-2025 | |
| Janssen Biotech, INC. | $52.73 | 2019 | |
| Pharmacosmos Therapeutics INC. | $46.42 | 2023-2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $44.59 | 2024-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $44.21 | 2023-2024 | Qinlock |
| Incyte Corporation | $23.78 | 2024 | Jakafi |
| Rigel Pharmaceuticals, INC. | $23.52 | 2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $22.76 | 2023 | Blincyto, Kyprolis |
| Beigene USA, INC. | $21.90 | 2024 | Brukinsa |
| Immunogen, INC. | $20.38 | 2023 | Elahere |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Emd Serono, INC. | $19.47 | 2023 | Bavencio |
| Janssen Pharmaceuticals, INC | $19.33 | 2023 | Xarelto |
| Recordati_rare_diseases_inc. | $17.99 | 2025 | Enjaymo |
| Lilly USA, LLC | $14.44 | 2024 | Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sueyi Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.